FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.
What happened
FDA reviewed a direct-to-consumer video titled “An Oprah Special: Shame, Blame, and the Weight Loss Revolution” about Zepbound and Mounjaro; it aired on ABC on March 18, 2024 and appeared on Hulu on March 19, 2024. FDA determined the video was false or misleading because it omitted or minimized serious risks, including boxed-warning risks, and because the video was not submitted at initial publication as required. FDA also cited prior advisory comments to Eli Lilly about similar risk-minimizing promotional presentations for Mounjaro.
What FDA found
FDA said the video made Zepbound and Mounjaro misbranded, meaning illegally labeled or promoted, because its risk presentation was false or misleading.
21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5)The video omitted the boxed warning (FDA’s strongest safety warning) contraindication for patients with a personal or family history of multiple endocrine neoplasia syndrome type 2, a thyroid cancer risk.
21 CFR 202.1(e)(5); (e)(7)(viii)The video omitted warnings about severe gastrointestinal disease, acute kidney injury, hypersensitivity reactions, hypoglycemia, diabetic retinopathy complications, and suicidal behavior and ideation.
21 CFR 202.1(e)(5)A paid consultant described pancreatitis, gallbladder complications, and thyroid cancer concerns as “hype” and said the risks were “less than 1%,” which FDA said minimized serious risks.
21 CFR 202.1(e)(5)The video gave only about four minutes to shared risks and no signpost to more risk information, so risk information was not presented with prominence comparable to benefits.
21 CFR 202.1(e)(5); (e)(7)(viii)Eli Lilly did not submit the video to FDA under Form FDA-2253 at the time it was first published.
21 CFR 314.81(b)(3)(i)
What FDA wants
FDA tells Eli Lilly to take immediate action, including ceasing misleading promotional communications, and to submit a written response within 15 working days of receipt that addresses the concerns, lists other similar promotional communications with Form FDA-2253 dates, and explains plans to discontinue them or cease distribution. It also requests a plan for corrective communications to the audiences that received the video.
Who should pay attention
- drug and device marketing review teams
- regulatory affairs teams for prescription drug advertising
- companies promoting GLP-1 receptor agonist products to consumers
This is a summary. Read the original letter on fda.gov.